OPEC study: An international multicenter study of ovarian preservation in endometrial cancers

Abstract

Objective To evaluate the feasibility and oncological safety of ovarian preservation in early stage endometrial adenocarcinoma (EC) patients aged 40 and below. Methods A total of 11 institutions from eight countries participated in the study. 169 of 5898 patients aged ≤40 years were eligible for the study. Patients with EC treated between March 2007 and January 2019 were retrospectively assessed. Results The median duration of follow‐up after EC diagnosis was 59 months (4–187). Among 169 participants, ovarian preservation surgery (OPS) was performed in 54 (31.9%), and BSO was performed in 115 (68.1%) patients. Although patients younger than 30 years of age were more likely to have OPS than patients aged 30 to 40 years (20.4% vs. 9.6%, P = 0.021), there was no significant difference by the mean age. There were no other relevant baseline differences between OPS and BSO groups. The Kaplan–Meier analysis revealed no difference in either the overall survival (P = 0.955) or recurrence‐free survival (P = 0.068) among patients who underwent OPS, and BSO. Conclusion OPS appears to be safe without having any adverse impact on survival in women aged ≤40 years with FIGO Stage I EC.

Ovarian preservation in gynecologic oncology: current indications and techniques

“…No difference in recurrence-free and OS was observed between the two groups. The authors concluded that ovarian preservation appears to be well tolerated without having any adverse impact on survival in women aged 40 years or less with FIGO-stage I endometrial cancer [20]. Interestingly, a recent case report described the ovarian recurrence 12 months after primary treatment of a postmenopausal woman with FIGO-stage IA grade 1 endometrioid endometrial adenocarcinoma [21].…”

“…Two retrospective studies specifically looked at the oncological safety of ovarian preservation in early-stage endometrial adenocarcinoma [19 ▪ ,20]. Nasioudis et al [19 ▪ ] analyzed 2941 patients aged 45 years or less diagnosed between January 2004 and December 2015 with FIGO-stage I grade 2 or 3 endometrioid endometrial carcinoma, who underwent hysterectomy with or without bilateral salpingo-oophorectomy from the National Cancer Database [19 ▪ ].…”